Is seputinib/serpatinib capsule an imported drug or a domestically produced drug?

Selpercatinib/Selpercatinib (Selpercatinib) is an imported drug. The drug is developed and produced by Eli Lilly and Company of the United States and has been approved for marketing in many countries, including the United States, the European Union, Japan, etc. In China, seputinib has also been approved for marketing by the National Medical Products Administration. Its indications include patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.

Seputinib is a drug used to treat cancers in which a specific gene has been altered (mutated or fused) in the tumor (RET stands for "rearrangement during transfection"). Seputinib is taken orally. Septinib is a kinase inhibitor, which means it blocks an enzyme (kinase) and helps stop cancer cells from growing. Before starting treatment, laboratory testing must be done to identify changes in the RET gene. Seputinibis the first therapy approved specifically for patients with cancer and RET gene alterations.

Up to now, the original research drug is sold in China under the name of Seputinib, but it is not included in medical insurance. The price of each box of 80mg*56 tablets may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Generic drugs of Seputinib have also been put on the market for sale overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*120 capsules produced by a Laos pharmaceutical factory is more than RMB 4,000 per box (the price may fluctuate due to exchange rates).